Immune Dysregulation in Patients with Severe Acute Pancreatitis

被引:46
|
作者
Shen, YinFeng [1 ]
Cui, NaiQiang [1 ]
Miao, Bing [1 ]
Zhao, ErPeng [1 ]
机构
[1] Tianjin Med Univ, Nankai Clin Sch, Nankai Hosp, Natl Med Ctr Biliopancreat Dis, Tianjin, Peoples R China
关键词
severe acute pancreatitis; immune dysregulation; cytokine; infection; organ dysfunction; TREATMENT STRATEGY; INJURY; RATS; EXPRESSION; MORTALITY; INFECTION; ALPHA; SERUM;
D O I
10.1007/s10753-010-9205-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To investigate patients with severe acute pancreatitis (SAP) by dynamic levels of pro-/anti-inflammatory cytokines and endotoxin (ET) in plasma and the relationship between immunity and infection, organ dysfunction. Seventy-two patients with SAP were recruited. The ET, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-4 (IL-4) were determined on admission and days 3, 7, and 14. For comparison, patients were analyzed through infection group versus non-infection group, multiple organ dysfunction syndrome (MODS) group versus non-MODS group. There were sixteen patients with secondary infection, twenty-two with MODS, and nine deaths. The infection group had higher levels of ET than the non-infection group on days 3 and 7. The dynamic cytokine levels of patients in the MODS group were unanimous with those outcomes in the infection group. The levels of cytokines in the infection group were different from the non-infection group, with more levels of TNF-alpha, IL-6 on days 3 and 7 and less on days 14, and more levels of IL-10, IL-4 on days7 and 14. The levels of TNF-alpha, IL-6 in the MODS group were different from the non-MODS group, with more levels on days 3 and 7, and less levels on days 14. Immune dysregulation may play an important role in infection and organ dysfunction for patients with SAP.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [31] Hemofiltration in Patients with Severe Acute Pancreatitis (Review)
    Boyarinov, G. A.
    Zubeyev, P. S.
    Mokrov, K., V
    Voyennov, O. V.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2020, 12 (01) : 105 - 121
  • [32] Fever and pustules in patients with severe acute pancreatitis
    Floristan Muruzabal, M. U.
    Feltes Ochoa, R. A.
    Feito Rodriguez, M.
    Arranz, D. M.
    Casado Jimenez, M.
    REVISTA CLINICA ESPANOLA, 2009, 209 (02): : 95 - 96
  • [33] The pharmacokinetics of vancomycin in patients with severe acute pancreatitis
    He, Juan
    Mao, En-Qiang
    Feng, Jing
    Jiang, Hui-Ting
    Yang, Wan-Hua
    Chen, Er-Zhen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (06) : 697 - 702
  • [34] Risk management in patients with severe acute pancreatitis
    Gerlach, H
    CRITICAL CARE, 2004, 8 (06): : 430 - 432
  • [35] The pharmacokinetics of vancomycin in patients with severe acute pancreatitis
    Juan He
    En-Qiang Mao
    Jing Feng
    Hui-Ting Jiang
    Wan-Hua Yang
    Er-Zhen Chen
    European Journal of Clinical Pharmacology, 2016, 72 : 697 - 702
  • [36] Risk management in patients with severe acute pancreatitis
    Herwig Gerlach
    Critical Care, 8
  • [37] Surgical Treatment of Patients with Severe Acute Pancreatitis
    Samara, M.
    Klimov, A. E.
    Persov, M. Yu
    Kirtadze, D. G.
    Barkhudarov, A. A.
    JOURNAL OF BIOCHEMICAL TECHNOLOGY, 2020, 11 (02) : 60 - 64
  • [39] Octreotide Treatment in Patients with Severe Acute Pancreatitis
    Haim Paran
    Ami Mayo
    Daphna Paran
    David Neufeld
    Ivan Shwartz
    Rika Zissin
    Pierre Singer
    Ofer Kaplan
    Yehuda Skornik
    Uri Freund
    Digestive Diseases and Sciences, 2000, 45 : 2247 - 2251
  • [40] Late mortality in patients with severe acute pancreatitis
    Gloor, B
    Müller, CA
    Worni, M
    Martignoni, ME
    Uhl, W
    Büchler, MW
    BRITISH JOURNAL OF SURGERY, 2001, 88 (07) : 975 - 979